First Patient Dosed With Drug Combo in Phase 2 Gastric Cancer Trial
A patient in a phase 2 trial has received the first dose of a novel combination of botensilimab and balstilimab plus agenT-979, an allogeneic cell therapy.
Source: curetoday.com
Stay updated with breaking news from Agent 797. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A patient in a phase 2 trial has received the first dose of a novel combination of botensilimab and balstilimab plus agenT-979, an allogeneic cell therapy.